^(99m)Tc-BDI-1导向诊断膀胱癌的临床研究

Targeting diagnosis of human bladder cancer with ^(99m)Tc-BDI-1

目的 评价 99mTc标记抗人膀胱癌单克隆抗体 (BDI 1)用于膀胱癌放射免疫显像 (RII)诊断的临床价值。 方法 采用 2 巯基乙醇直接还原法将 99mTc与BDI 1进行标记 ,制备 99mTc BDI 1。将其灌入 12例非膀胱癌及 32例膀胱癌患者的膀胱内 ,用γ 照相机采集图像 ,根据放射性异常浓聚作出诊断。 结果 12例非膀胱癌患者均为阴性显像 ,32例膀胱癌患者 30例 (94% )显像。先于膀胱镜检 3个月发现早期复发癌 2例。膀胱癌组织摄取 99mTc BDI 1的程度随肿瘤分级而增加。血样本未检出放射性。 结论 99mTc BDI 1导向膀胱癌的诊断是一种安全可靠的诊断方法。

Objective To investigate 99m Tc labeled antihuman bladder cancer antibody BDI-1 for the detection of human bladder cancer. Methods Anti-human Bladder carcinoma cell line BIU-87 monoclonal antibody BDI-1 was labeled with 99m Tc by direct mercaptoethanol reducing method and the 99m Tc-BDI-1 was instilled into the bladder of 32 bladder cancer patients and 12 non-cancer patients. Results The labeling rate was 72% and the radiochemical purity was higher than 95%;the binding rate with E-J cell line was 90%. 44 patients received radioimmunoimaging. 12 nontumor patients was negative. In 32 bladder tumor patients, the positive rate, the negative rate and the false positive rate were 94%,6% and 0 respectively; Both primary and recurrent tumor could be detected clearly and 2 early recurrent tumors were found three months prior to cystoscopy; the uptake of 99m Tc-BDI-1 by tumor was higher than by normal epithelium,inreasing with the tumor grade. No radioactivity was detected in blood samples. Conclusions The targeting diagnosis of bladder cancer with 99m Tc-BDI-1 is a useful and reliable new method.